Targeting cancer by inducing senescence

Open Enzyme Inhibition Journal

Volumn 3, Issue 1, 2010, Pages 46-52

  Marin, Juan José ^a   Vergel, Mar ^b   Carnero, Amancio ^b,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c CSIC   (Spain)

Author keywords

Cellular senescence; Immortality; Senescence targets; Telomere shortening

Indexed keywords

EID: 84926329267     PISSN: None     EISSN: 18749402     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. [1] Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-36.
2. [2] Thomas E, al-Baker E, Dropcova S, et al. Different kinetics of senescence in human fibroblasts and peritoneal mesothelial cells. Exp Cell Res 1997; 236: 355-8.
3. [3] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
4. [4] Untergasser G, Koch HB, Menssen A, Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res 2002; 62: 6255-62.
5. [5] Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic ras-induced senescence. Oncogene 2004; 23: 9238-46.
6. [6] Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005; 7: 816-23.
7. [7] Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23: 2919-33.
8. [8] te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62: 1876-83.
9. [9] Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-40.
10. [10] Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol 2001; 13: 748-53.
11. [11] Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007; 1775: 5-20.
12. [12] Mooi WJ, Peeper DS. Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med 2006; 355: 1037-46.
13. [13] Carnero A, Lleonart ME. Epigenetic mechanisms in senescence, immortalisation and cancer. Biol Rev Camb Philos Soc 2010. [Epub ahead of print]
14. [14] Vergel M, Carnero A. Bypassing cellular senescence by genetic screening tools. Clin Transl Oncol 2010; 12: 410-7.
15. [15] Castro ME, Ferrer I, Cascon A, et al. PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis 2008; 29: 491-9.
16. [16] Leal JF, Ferrer I, Blanco-Aparicio C, et al. S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis 2008; 29: 2089-95.
17. [17] Lleonart M, Vidal F, Gallardo D, et al. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncol Rep 2006; 16: 603-8.
18. [18] Leal JF, Fominaya J, Cascon A, et al. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene 2008; 27: 1961-70.
19. [19] Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177-85.
20. [20] Fridman AL, Rosati R, Li Q, Tainsky MA. Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization. Biochem Biophys Res Commun 2007; 357: 785-91.
21. [21] Kortlever RM, Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 2006; 5: 2697-703.
22. [22] Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8: 877-84.
23. [23] Wang W, Chen JX, Liao R, et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002; 22: 3389-403.
24. [24] Haq R, Brenton JD, Takahashi M, et al. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res 2002; 62: 5076-82.
25. [25] Zhang H, Cohen SN. Smurf2 up-regulation activates telomeredependent senescence. Genes Dev 2004; 18: 3028-40.
26. [26] Shibanuma M, Mochizuki E, Maniwa R, et al. Induction of senescence-like phenotypes by forced expression of hic-5, which encodes a novel LIM motif protein, in immortalized human fibroblasts. Mol Cell Biol 1997; 17: 1224-35.
27. [27] Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-4.
28. [28] Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436: 642.
29. [29] Lazzerini Denchi E, Attwooll C, Pasini D, Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005; 25: 2660-72.
30. [30] Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53- dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-30.
31. [31] Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436: 660-5.
32. [32] Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63: 2705-15.
33. [33] Carnero A, Link W, Martinez JF, et al, Cellular senescence and cancer. Res Adv Cancer 2003; 3: 183-98.
34. [34] Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci USA 1988; 85: 6042-6.
35. [35] McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998; 8: 351-4.
36. [36] Carnero A, Hudson JD, Hannon GJ, Beach DH. Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acids Res 2000; 28: 2234-41.
37. [37] Carnero A. Targeting the cell cycle for cancer therapy. Br J Cancer 2002; 87: 129-33.
38. [38] Ball KL, Lain S, Fahraeus R, Smythe C, Lane DP. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 1997; 7: 71-80.
39. [39] Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-46.
40. [40] Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
41. [41] Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-15.
42. [42] Roninson IB. Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat 2002; 5: 204-8.
43. [43] Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 1999; 93: 2380-5.
44. [44] Carter TL, Watt PM, Kumar R, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood 2001; 97: 572-4.
45. [45] Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677-85.
46. [46] Chen QM. Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann NY Acad Sci 2000; 908: 111-25.
47. [47] Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59: 3761-7.
48. [48] Wang X, Wong SC, Pan J, et al. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res 1998; 58: 5019-22.
49. [49] Yeo EJ, Hwang YC, Kang CM, et al. Senescence-like changes induced by hydroxyurea in human diploid fibroblasts. Exp Gerontol 2000; 35: 553-71.
50. [50] Michishita E, Nakabayashi K, Suzuki T, et al. 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. J Biochem 1999; 126: 1052-9.
51. [51] Chang BD, Xuan Y, Broude EV, et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999; 18: 4808-18.
52. [52] Elmore LW, Rehder CW, Di X, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002; 277: 35509-15.
53. [53] Gire V, Roux P, Wynford-Thomas D, Brondello JM, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 2004; 23: 2554-63.
54. [54] Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell 2006; 17: 1583-92.
55. [55] Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, Howley PM. Papillomavirus E2 induces senescence in HPVpositive cells via pRB- and p21(CIP)-dependent pathways. EMBO J 2000; 19: 5762-71.
56. [56] Lodygin D, Menssen A, Hermeking H. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53- independent manner. J Clin Invest 2002; 110: 1717-27.
57. [57] Roninson IB, Dokmanovic M. Induction of senescence-associated growth inhibitors in the tumor-suppressive function of retinoids. J Cell Biochem 2003; 88: 83-94.
58. [58] Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
59. [59] Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-70.
60. [60] Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
61. [61] Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-12.
62. [62] Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006; 107: 2680-5.
63. [63] Marciniak R, Guarente L. Human genetics. Testing telomerase. Nature 2001; 413: 370-1, 373.
64. [64] Artandi SE, DePinho RA. Mice without telomerase: what can they teach us about human cancer? Nat Med 2000; 6: 852-5.
65. [65] Holt SE, Wright WE, Shay JW. Multiple pathways for the regulation of telomerase activity. Eur J Cancer 1997; 33: 761-6.
66. [66] Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13: 2388-99.